This is a summary of the European public assessment report (EPAR) for Bretaris Genuair. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Bretaris Genuair.
For practical information about using Bretaris Genuair, patients should read the package leaflet or contact their doctor or pharmacist.
Bretaris Genuair : EPAR - Summary for the public (PDF/75.86 KB)
First published: 19/09/2012
Last updated: 19/06/2017
Bretaris Genuair : EPAR - Risk management plan summary (PDF/112.07 KB)
First published: 02/07/2021
Last updated: 02/07/2021
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Pulmonary Disease, Chronic Obstructive
|Anatomical therapeutic chemical (ATC) code||
|Date of issue of marketing authorisation valid throughout the European Union||
31/05/2021 Bretaris Genuair - EMEA/H/C/002706 - IG1394/G
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Drugs for obstructive airway diseases
Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).